Insider · CIK 0001671311
Jennifer Jarrett
Files at SNDX (Syndax Pharmaceuticals Inc), SGMT (Sagimet Biosciences Inc.), RCUS (Arcus Biosciences, Inc.), DMRA (Galecto, Inc.), ZURA (Zura Bio Ltd). First filing Dec 26, 2023, latest Sep 28, 2026.
In brief
Jennifer Jarrett files SEC Form 4 as COO, director, CEO and president at RCUS (Arcus Biosciences, Inc.), and also at DMRA (Galecto, Inc.), SNDX (Syndax Pharmaceuticals Inc), SGMT (Sagimet Biosciences Inc.), ZURA (Zura Bio Ltd). Since Dec 26, 2023, Jennifer Jarrett has reported 1 open-market buy worth $253k and 7 open-market sells worth $4.2M, the latest filed on Sep 28, 2026.
A track record needs three past buys with six months of prices behind them; Jennifer Jarrett has 0, so none is measured yet.
The newest scored trade: bought $253k of DMRA on Sep 25, 2026, filed Sep 28, 2026, scored 38 (weak). In the last 12 months: 1 buy worth $253k and 2 sells worth $1.4M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
RCUS: Arcus Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
DMRA: Galecto, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | DMRAbuy Galecto, Inc. | $253k 12,500 shares | +3% | - | |
| 32Weak | Arcus Biosciences, Inc. | $467k 21,208 shares | -10% | +223% from low-15% from high | |
| 29Weak | Arcus Biosciences, Inc. | $954k 50,291 shares | -19% | +181% from low-5% from high | |
| 20Weak | Arcus Biosciences, Inc. | $750k 50,292 shares | -22% | +111% from low-21% from high | |
| 12Weak | Arcus Biosciences, Inc. | $203k 11,551 shares | -5% | +36% from low-23% from high | |
| 13Weak | Arcus Biosciences, Inc. | $241k 13,449 shares | -6% | +28% from low-27% from high | |
| 38Weak | Arcus Biosciences, Inc. | $1.2M 58,625 shares | -20% | +46% from low-16% from high | |
| 31Weak | Arcus Biosciences, Inc. | $382k 21,521 shares | -8% | +35% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 6, 2026 | RCUS ARCUS BIOSCIENCES, INC. | 77,793 0.06% of outstanding | $1.9M | May 6, 2026 | $2.9M |
| Apr 23, 2026 | RCUS ARCUS BIOSCIENCES, INC. | 53,826 0.04% of outstanding | $1.4M | Apr 23, 2026 | $1.6M |
| Apr 8, 2026 | RCUS ARCUS BIOSCIENCES, INC. | 70,000 0.06% of outstanding | $1.6M | Apr 8, 2026 | none |
| Dec 15, 2025 | RCUS Arcus Biosciences, Inc. | 22,000 0.02% of outstanding | $482k | Dec 16, 2025 | $1.7M |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | 100,583 0.09% of outstanding | $1.3M | Oct 6, 2025 | none |
| Mar 27, 2024 | RCUS Arcus Biosciences, Inc. | 56,551 0.06% of outstanding | $956k | Mar 27, 2024 | $1.2M |
| Mar 15, 2024 | RCUS Arcus Biosciences, Inc. | 16,000 0.02% of outstanding | $296k | Mar 18, 2024 | $2.0M |
| Dec 22, 2023 | RCUS Arcus Biosciences, Inc. | 80,146 0.11% of outstanding | $1.4M | Dec 22, 2023 | none |
| Dec 15, 2023 | RCUS Arcus Biosciences, Inc. | 16,000 0.02% of outstanding | $280k | Dec 18, 2023 | $682k |
Transactions
Every row this insider has filed, 37 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | DMRA Galecto, Inc. | POpen-market purchase Ordinary Shares | +12,500 | $20.23 | $253k | 512,500 | 16 d ago |
| Jun 17, 2026 | ZURA Zura Bio Ltd | AGrant or award Share Option (Right to Buy)derivative | +51,000 | $0.00 | $0 | 51,000 | Jun 22, 2026 |
| Jun 12, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +39,567 | $0.00 | $0 | 39,567 | Jun 15, 2026 |
| Mar 30, 2026 | DMRA Galecto, Inc. | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 500,000 | Apr 1, 2026 |
| Mar 30, 2026 | DMRA Galecto, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,500,000 | $0.00 | $0 | 1,500,000 | Apr 1, 2026 |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 114,000 | Feb 6, 2026 |
| Jan 23, 2026 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +31,000 | $0.00 | $0 | 224,024 | Jan 26, 2026 |
| Jan 23, 2026 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +126,000 | $0.00 | $0 | 126,000 | Jan 26, 2026 |
| Dec 16, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -11,225 | $21.88 | $246k | 203,007 | Dec 18, 2025 |
| Dec 17, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -9,983 | $22.16 | $221k | 193,024 | Dec 18, 2025 |
| Nov 7, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +50,291 | $1.23 | $62k | 264,523 | Nov 12, 2025 |
| Nov 7, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -50,291 | $18.97 | $954k | 214,232 | Nov 12, 2025 |
| Nov 7, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,291 | $1.23 | $62k | 80,583 | Nov 12, 2025 |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +12,500 | $1.23 | $15k | 226,732 | Oct 8, 2025 |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -12,500 | $14.54 | $182k | 214,232 | Oct 8, 2025 |
| Oct 8, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +37,792 | $1.23 | $46k | 252,024 | Oct 8, 2025 |
| Oct 8, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -37,792 | $15.05 | $569k | 214,232 | Oct 8, 2025 |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,500 | $0.00 | $0 | 168,666 | Oct 8, 2025 |
| Oct 8, 2025 | RCUS Arcus Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,792 | $0.00 | $0 | 130,874 | Oct 8, 2025 |
| Jun 9, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +27,268 | $0.00 | $0 | 27,268 | Jun 10, 2025 |
| May 21, 2025 | ZURA Zura Bio Ltd | AGrant or award Share Option (Right to Buy)derivative | +51,000 | $0.00 | $0 | 51,000 | May 22, 2025 |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 90,000 | Feb 7, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 213,369 | Jan 27, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jan 27, 2025 |
| Dec 15, 2024 | RCUS Arcus Biosciences, Inc. | FTax withholding Common Stock | -27,501 | $16.08 | $442k | 163,369 | Dec 17, 2024 |
| Dec 9, 2024 | ZURA Zura Bio Ltd | AGrant or award Share Option (Right to Buy)derivative | +117,000 | $0.00 | $0 | 117,000 | Dec 11, 2024 |
| Mar 27, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -11,551 | $17.55 | $203k | 215,253 | Mar 29, 2024 |
| Mar 18, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -12,153 | $17.84 | $217k | 228,100 | Mar 20, 2024 |
| Mar 18, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,296 | $18.62 | $24k | 226,804 | Mar 20, 2024 |
| Feb 26, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -24,555 | $20.07 | $493k | 274,323 | Feb 28, 2024 |
| Feb 27, 2024 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -34,070 | $20.11 | $685k | 240,253 | Feb 28, 2024 |
| Feb 7, 2024 | SNDX Syndax Pharmaceuticals Inc | AGrant or award Common Stock | +17,000 | $0.00 | $0 | 65,000 | Feb 9, 2024 |
| Jan 23, 2024 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 298,878 | Jan 25, 2024 |
| Jan 23, 2024 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +162,400 | $0.00 | $0 | 162,400 | Jan 25, 2024 |
| Dec 22, 2023 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -21,521 | $17.76 | $382k | 258,878 | Dec 26, 2023 |
| Dec 18, 2023 | RCUS Arcus Biosciences, Inc. | DDisposition to issuer Common Stock10b5-1 | -11,250 | $17.74 | $200k | 291,891 | Dec 20, 2023 |
| Dec 19, 2023 | RCUS Arcus Biosciences, Inc. | DDisposition to issuer Common Stock10b5-1 | -11,492 | $18.09 | $208k | 280,399 | Dec 20, 2023 |
Questions about Jennifer Jarrett
Answered from the filings on this page, as of the latest one.
Is Jennifer Jarrett buying or selling?
In the last 12 months Jennifer Jarrett reported 1 open-market buy worth $253k and 2 open-market sells worth $1.4M on SEC Form 4; the latest was bought $253k of DMRA on Sep 25, 2026. Grants, option exercises and tax withholding are not counted.
How did Jennifer Jarrett's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jennifer Jarrett has 0.
Where does Jennifer Jarrett file Form 4?
Jennifer Jarrett has filed Form 4 at RCUS (Arcus Biosciences, Inc.) as Chief Operating Officer; DMRA (Galecto, Inc.) as See Remarks; SNDX (Syndax Pharmaceuticals Inc); SGMT (Sagimet Biosciences Inc.); ZURA (Zura Bio Ltd). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.